Purchase Order 36C24226P0360
Award Date 2/4/26
Potential Completion Date 5/4/26
Potential Value $29K
Federal Agency
Awardee
Ultimate Awardee
NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Wildwood, MO 63005, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm fixed price purchase order contract awarded by the Department of Veterans Affairs Veterans Health Administration to Foundation Care LLC, a specialty pharmacy, to provide the drug Iclusig (ponatinib). The contract has a potential value of $110,424.15 and a completion date of September 30, 2022. Foundation Care LLC is a subsidiary of Centene Corporation, a for-profit organization. The contract does not have a set-aside designation. Through this and other federal contract awards,...
- This federal contract award to Foundation Care LLC, a full-service retail and specialty pharmacy, is for the drug Iclusig (ponatinib) for $115,946.48. The contract is a purchase order from the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21, with a completion date of September 30, 2021. The contract has no set-aside designation. Foundation Care LLC is a subsidiary of the for-profit organization Centene Corporation. Through this and over 60...
- Foundation Care LLC, a for-profit specialty pharmacy and subsidiary of Centene Corporation, has been awarded a $13,956.72 firm-fixed-price purchase order contract by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 6. The contract is for the provision of Iclusig 15 mg tablets to the Earth City, Missouri VA medical center, with a period of performance through February 29, 2024. Iclusig is used to treat chronic myeloid leukemia and...
- Foundation Care LLC, a for-profit specialty pharmacy and subsidiary of Centene Corporation, has been awarded a $24,538.70 firm fixed price purchase order contract by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 located in Palo Alto, California. The contract is for the provision of Iclusig (ponatinib), a medication used to treat certain types of leukemia and blood disorders. Performance will take place in Palo Alto and be completed by...
- This federal contract award is for the supply of CHEMOTHERAPY MEDICATION, specifically the drug Iclusig (ponatinib) and other ponatinib medications, to the Federal Medical Center Lexington, a civilian agency under the Department of Veterans Affairs (VA). The $28,980.78 Firm Fixed Price award was granted to Foundation Care LLC, a specialty pharmacy and subsidiary of the larger healthcare organization Centene Corporation. The contract does not have a set-aside designation and is for a term...
- Takeda Pharmaceuticals America, Inc., a foreign-owned biopharmaceutical manufacturer and subsidiary of Takeda Pharmaceutical Company Limited, was awarded a delivery order on July 31, 2025, for ICLUSIG 15 mg (ponatinib), an oncology medication, with a ceiling value of $14,197.39. This firm fixed-price delivery order was issued without a small business set-aside and is set to be completed by August 5, 2025. The contract will be performed in Earth City, Missouri, and is funded by Veterans...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 10 awarded a $26,250 firm fixed price purchase order to Foundation Medicine, Inc. to provide maintenance services for the Hematologic NGS Hematologic Malignancies Panels at the Richard L. Roudebush VA Medical Center in Indianapolis, Indiana. This order was issued under Foundation Medicine's indefinite delivery contract with the VA Headquarters, valued at over $111 million, to support VA...
- This is a firm fixed-price Blanket Purchase Agreement (BPA) call issued by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 7 (VISN 7) to Ariad Pharmaceuticals, Inc. for the order of pharmaceuticals, specifically cancer drugs such as Iclusig (ponatinib) and Lenvima (lenvatinib), for the Department of Veterans Affairs in fiscal year 2017. The contract has a ceiling value of $108,039.90 and an ultimate completion date of September 30, 2017. This contract was awarded...
- The Department of Veterans Affairs, Veterans Integrated Service Network (VISN) 20, awarded a delivery order contract to Takeda Pharmaceuticals America, Inc. for the supply of ICLUSIG 30mg tablets, valued at $173,715.75 under a firm fixed-price arrangement. The contract was awarded on May 10, 2024, with an ultimate completion date of May 9, 2025, and carries no small business set-aside designation. The pharmaceutical products will be delivered to a facility in Earth City, Missouri. This...
- The U.S. Department of Veterans Affairs (VA) awarded a $173,208.96 firm-fixed-price delivery order contract to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, to provide bulk orders of the oncology medication ICLUSIG (ponatinib). The contract was issued against Takeda's existing General Services Administration (GSA) Schedule 61-IB for Pharmaceuticals and Drugs and supports the VA's provision of specialized cancer treatments to veterans nationwide....